

**AAO30: Early Oral Cancer: Staging and Treatment** 

High Priority: No

Percentage of patients with a diagnosis of oral cavity cancer seen in the practice setting who have a TNM cancer stage documented in the medical record within one month of the first office visit AND who receive treatment if identified with a primary tumor depth > 4 mm.

## **Denominator:**

- 1. Patients aged 18 and older diagnosed with early oral cavity cancer.
- 2. Patients 18 years or older diagnosed with clinical node negative (clinical state T1N0M0 or T2N0M0) oral cavity cancer with the depth of the primary tumor > 4mm documented in the medical record within one month of the first office visit.

#### **Denominator Exclusions:**

Exclude patients who expire prior to treatment.

### **Denominator Exceptions:**

Medical reasons for not performing surgical treatment or patient refusal of treatment.

#### Numerator:

- 1. Patients for which cancer stage at the diagnosis is documented in the medical record within 31 days of the first office visit.
- 2. Patients who receive any of the following surgical treatment of the primary tumor: Sentinel lymph node biopsy, elective neck dissection, definitive radiation.

### Measure Classifications:

Measure Type: Process

National Quality Strategy (NQS) domain: Effective Clinical Care Meaningful Measure Area: Appropriate Use of Healthcare

Calculation: Weighted Average Inverse Measure: No Continuous Measure: No Proportional Measure: Yes

> Ratio Measure: No Risk Adjusted: No

#### Copyright:

© 2019 American Academy of Otolaryngology - Head and Neck Surgery Foundation. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g. use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measures require a license agreement between the user and the American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF).

Disclaimer: The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

Empowering otolaryngologist-head and neck surgeons to deliver the best patient care

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. Neither the AAO-HNSF nor its members shall be responsible for any use of the Measures. The AAO-HNSF and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.
Empouvering otalog magalogist hand and neels as grant and allies at the best matient and
Empowering otolaryngologist-head and neck surgeons to deliver the best patient care

**EVIDENCE-BASED CARE** 


**QCDR** Measure Flow for:

# **AAO30**


**Early Oral Cancer: Staging and Treatment** 

#### **MEASURE DESCRIPTION**

Percentage of patients with a diagnosis of early oral cavity cancer\* seen in the practice setting who have a TNM cancer stage documented in the medical record within one month of the first office visit AND who receive treatment if identified with a primary tumor depth > 4 mm.



\*Early oral cavity cancer is cancer staged T1NOMO or T2NOMO



# NUMERATOR

